2890. Pharmacokinetics, Safety, and Efficacy of Ceftazidime-Avibactam in Neonates and Young Infants with Bacterial Infections: Results from a Phase 2a, 2-part, Open-label, Non-randomized, Multicenter Trial

John S Bradley; Emmanuel Roilides; Richard England; Margaret Tawadrous; Jean Yan; Elena Soto; Gregory Stone; Shweta Kamat

Journal ArticleOPEN ACCESS

2890. Pharmacokinetics, Safety, and Efficacy of Ceftazidime-Avibactam in Neonates and Young Infants with Bacterial Infections: Results from a Phase 2a, 2-part, Open-label, Non-randomized, Multicenter Trial

Bradley J
Roilides E
England R
et al.

Open Forum Infectious Diseases (2023) 10(Supplement_2)

DOI: 10.1093/ofid/ofad500.2473

N/ACitations

3Readers

Abstract

80 serum neutralizing an-tibody (SNA) titers at selected timepoints. Seroresponse rate (SRR) was the percentage of participants who achieved NT 80 SNA titer ≥ 100 (FDA/EMA agreed threshold). Safety outcomes were evaluated through monitoring adverse events (AEs) through Day 183.

Cite

CITATION STYLE

APA

Bradley, J. S., Roilides, E., England, R., Tawadrous, M., Yan, J., Soto, E., … Kamat, S. (2023). 2890. Pharmacokinetics, Safety, and Efficacy of Ceftazidime-Avibactam in Neonates and Young Infants with Bacterial Infections: Results from a Phase 2a, 2-part, Open-label, Non-randomized, Multicenter Trial. Open Forum Infectious Diseases, 10(Supplement_2). https://doi.org/10.1093/ofid/ofad500.2473

2890. Pharmacokinetics, Safety, and Efficacy of Ceftazidime-Avibactam in Neonates and Young Infants with Bacterial Infections: Results from a Phase 2a, 2-part, Open-label, Non-randomized, Multicenter Trial

Abstract

Cite

Register to see more suggestions